Canakinumab - CaLiGraph

CaLiGraph

Property	Value
rdf:type	Antineoplastic drug owl:NamedIndividual Monoclonal antibody Novartis brand Therapeutic monoclonal antibody Drug granted breakthrough therapy designation
rdfs:label	Canakinumab
owl:sameAs	dbr:Canakinumab
prov:wasDerivedFrom	http://en.wikipedia.org/wiki/List_of_drugs:_C%E2%80%93Ca http://en.wikipedia.org/wiki/List_of_drugs:_Ia%E2%80%93Il http://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies http://en.wikipedia.org/wiki/Category:Antineoplastic_drugs http://en.wikipedia.org/wiki/Antiarthritics http://en.wikipedia.org/wiki/Category:Monoclonal_antibodies http://en.wikipedia.org/wiki/Category:Novartis_brands http://en.wikipedia.org/wiki/Monoclonal_antibody_therapy http://en.wikipedia.org/wiki/Novartis http://en.wikipedia.org/wiki/List_of_drugs_granted_breakthrough_therapy_designation http://en.wikipedia.org/wiki/Muckle%E2%80%93Wells_syndrome http://en.wikipedia.org/wiki/Mevalonate_kinase_deficiency
skos:prefLabel	Canakinumab
skos:altLabel	Ilaris canakinumab canosimibe
clgo:alternativeName	Ilaris
clgo:casNumber	914613-48-2
clgo:chEMBL	1201834
clgo:drugbank	DB06168
clgo:fdaUniiCode	37CQ2C7X93
clgo:kegg	D09315
is clgo:treatment of	Pyoderma gangrenosum

About: clgr:Canakinumab